Navigation Links
Arpida Announces Full Year 2007 Financial Results
Date:3/13/2008

REINACH, Switzerland, March 13 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the year ending 31 December 2007.

2007 highlights

Major pipeline progress:

- Second pivotal Phase III trial with intravenous iclaprim in cSSSI achieves its pre-specified primary endpoint, as did the first

- Submission of New Drug Application (NDA) for intravenous iclaprim in cSSSI initiated

- First patients enrolled in a Phase II trial with intravenous iclaprim in HAP/VAP/HCAP, an important potential second indication
- Progress of Phase I programme with oral iclaprim

- Promising results of 'first-in-man' studies with AR-709

- Novel antibiotic AR-2474 achieves preclinical proof of concept

- Raised CHF 51.9 million in a secondary offering in March 2007 - Late-stage antifungal therapy added to pipeline via acquisition of TLT Medical Ltd.
- Extensive presence at scientific conferences

- Cash and financial investments of CHF 68.1 million at 31 December 2007

Post-Year-End Events

- Oral iclaprim moves into Phase II efficacy trial in cSSSI

2008 Outlook - Completion of patient enrolment in Phase II trial with oral iclaprim in cSSSI

- Completion of patient enrolment in Phase II trial with intravenous iclaprim in

HAP/VAP/HCAP

- Completion of patient enrolment in Phase III trial with TLT in onychomycosis

- Regulatory review of NDA for intravenous iclaprim in cSSSI in USA

- Submission of application for marketing authorisation in EU

Dr Khalid Islam, President and CEO, commented: "We're tremendously proud of the progress we've achieved in the year under review. By early 2008, we have one product candidate in an NDA filing process, one product in a Phase III, and two additional Phase II development programs. We are expecting the filing of the NDA for intravenous iclaprim in cSSSI to be completed shortly. Mark
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
3. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
4. Arpida-Supported CME Symposium Available Online
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. Arpida Interim Results for six Months to 30 June 2007
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... everyone has heard of identity theft (IDT), yet unless you ... at high risk. An alarming figure is that over half ... a place of business, employer, or other entity (not-for-profit or ... individuals are required under one or more federal and state ...
... American angel investors continue to be the largest source of ... in the first half of 2006, an increase of 15 ... Center for Venture Research at the University of New ... research on the angel market since 1980, reported that healthcare ...
... had a crystal ball that could help him predict the ... president and research fellow at Yahoo , has a ... called "the cash cow with a big target on it." ... user-generated content (combined with search) that will somehow enable professionals ...
Cached Biology Technology:Identity theft: The business time bomb 2Identity theft: The business time bomb 3Identity theft: The business time bomb 4Angel investors commit $12.7B in first half of `06 2Online communities may be next business market 2Online communities may be next business market 3
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... sparrow-sized fossil from China challenges the commonly held belief ... the ability to fly. The birdlike fossil is actually ... the remains of a tiny tree-climbing animal that could ... Museum in Blanding, Utah, and Alan Feduccia of the ... Journal of Ornithology . , The fossil of ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Elsevier, a world-leading provider of scientific, technical and ... a new, international, open access journal, Case Studies ... Studies in Engineering Failure Analysis provides a forum ... Studies in Engineering Failure Analysis and will form ...
... of several of the most external atomic layers of ... Analysis by a number of modern techniques. Just opened ... Academy of Sciences, Warsaw, Poland, the Centre provides a ... electron microscope and specialised spectroscopic equipment for surface studies ...
... PHOENIX, Nov. 26, 2012 Webcast AdvisoryWhat:Announcement of a ... internationally respected team racing to unlock genomic codes ... lead to biomedical breakthroughs that will give new ... diagnoses.Who:Phoenix Children,s Hospital, in collaboration with Translational Genomics ...
Cached Biology News:Elsevier launches new open access journal -- 'Case Studies in Engineering Failure Analysis' 2Surface analysis techniques for advanced materials enhance Mazovia's research potential 2Surface analysis techniques for advanced materials enhance Mazovia's research potential 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: